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The services for drug-dependence treatment and care, particularly in low-income coun-
tries, should not be fragmented and uncoordinated. A basic package of interventions
should be provided in the same place and managed by the same team, with a one-stop-
shop approach. The services for substance use disorders should be appealing, accessible,
voluntary-based, and science-based. They should also, like efforts to fight other diseases,
be included in the community and the public health systems; that is, those who are
affected by drug use and those who serve them should not face discrimination. The first-
line assistance and the second-line essential elements of the comprehensive package are
described in this article. The work of the United Nations Office on Drugs and Crime
(UNODC) and the World Health Organization (WHO) to promote science-based and
voluntary-based ethical treatment in Asia is also illustrated.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license.1. Introduction 2. Where are the patients?The United Nations Office on Drugs and Crime (UNODC) and
theWorld Health Organization (WHO) are global leaders in the
fight against illicit drug use and dependence. Many parts of
East Asia have high prevalence of the use of opioids,
amphetamine, and other drugs, aswell as high rates of human
immunodeficiency virus (HIV) infection. To address drug use
and its related disorders, it is necessary to take into account
the health, socioeconomic, and security implications of drug
use. This article focuses on treatment and describes compre-
hensive, integrated health-based approaches to drug policies
that can reduce demand for illicit substances, relieve
suffering, and decrease drug-related harm to individuals,
families, communities, and societies.(G. Gerra).
ministration, Taiwan. PublA survey of 11 countries in East Asia showed that almost all
countries reported provision of various drug-dependence
treatment and care services outside of prison settings (e.g.,
detoxification, maintenance, counseling, peer-support
groups, etc.), but less than half indicated high coverage
levels of these services in their countries. It has been esti-
mated or reported that there are 1.3 million drug users in
Thailand; 154,000 registered drug users in Vietnam; 40,000
problem drug users in Cambodia; and 1,826,000e2,350,000
injection drug users (IDUs) in China; 20% of IDUs being HIV
positive and 36.7% of IDU sharing syringes that were associ-
ated with methamphetamine use. However, there are only a
small number of voluntary-based treatment facilities for drugished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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In other words, there are hundreds of thousands of drug users
in need of treatment for drug dependence, but only a few
thousand are in treatment. These discrepancies raise the
question, where are the drug-dependent patients? Are they in
contact with health institutions? Are they offered social pro-
tection and recovery opportunities?
Treatment centers are not appealing to those who need
them and are not well attended. In many countries, instead of
providing treatment or care, officials only want to “clean the
streets” of drug usersdthey are patients whom no one wants.
The collective denial involves stigma and discrimination.
Large numbers of drug users are in compulsory treatment or
detention centers, and those facilities treat drug users using
methods that are not based on scientific evidence.3. The disease is complex, but the response
of treatment has been poor
Addiction is a chronic disease that involves a complex path-
ogenesis. The psychobiological vulnerability includes synaptic
function, epigenetic changes [1,2], behavioral attitudes, and
mental health disorders. Many factors contribute to vulnera-
bility to the disease, ranging from parental neglect and abuse
in childhood, peer pressure, stressful life events, drug avail-
ability, to social exclusion or extreme poverty. However,
treatment response to this complex disease has been poor. For
example, there are few outpatient services and no medica-
tions for amphetamine-type stimulant (ATS)-dependent pa-
tients. Most methadone clinics treat a limited number of
patients and have long waiting lists. During my missions
around the world, I have witnessed striking barriers to pa-
tients receiving methadone, for example, the requirement to
be HIV positive, to have previously failed detoxification, to be
registered by the police office, or to be in a residential meth-
adone program for 1 month. Furthermore, it is often observed
that among drug treatments, buprenorphine is abused and
naltrexone is ignored in many countries.4. What has to be done?
First-line social assistance, withmeasures aimed at creating a
sustainable livelihood for patients, is the main element that
makes drug treatment services appealing to a large number of
people. A strong outreach component is also needed, one that
possibly uses volunteers (including former drug users), is
nonjudgmental and nonconfrontational, and is coordinated
with the police. These measures help people to survive.
Outreach techniques permit service providers to reach drug-
dependent individuals who are not motivated to seek treat-
ment and who live in marginalized conditions. Risk reduction
and healthcare interventions, together with hygienic mea-
sures, are also essential.
The second-line essential element of the comprehensive
package of interventions is the use of appropriate medica-
tions. Opiate substitution treatment provided asmaintenance
therapy has been found to be associated with a reduction in
the risk of HIV infection among people who inject drugs.Unfortunately, opioid agonist therapy is not permitted in
many countries for ideological reasons and legislative
barriers.
There are many studies showing that science-based,
ethical, and voluntary-based accessible drug-dependence
treatment is cost-effective. For example, a study by Kimber
et al [3] has shown that a longer period of substitution treat-
ment is associated with a lower risk of death. Based on a
systematic meta-analysis on studies implemented between
1992 and 2009 in China, the United States, Canada, the United
Kingdom, Thailand, Austria, Italy, and TheNetherlands, it was
found that opioid substitution treatment provided as main-
tenance therapy was associated with a 54% reduction in the
risk of HIV infection among people who inject drugs [4]. A
study in China (Ni et al, 2012) [5] found that 5678HIV infections
were averted between 2005 and 2010, and the treatment costs
saved per dollar increased steadily from 1.21 in 2006 to 8.22 in
2010. In Iran, methadone maintenance has reduced injection
from 100% to 16% and syringe sharing from 40% to 45%, aswell
as improved relationships within families and between part-
ners [6]. Furthermore,Metzger and Zhang [7] showed that drug
treatment as HIV prevention has shown reductions in the
frequency of drug use, risk behaviors, and HIV infection, and
so they suggest the expansion of treatment options such as
methadone, buprenorphine/naloxone, and naltrexone. There
are now many opportunities for opioid medications. Inject-
able and implantable sustained-release naltrexone in the
treatment of opioid addiction reduces risk behavior for blood-
borne diseases such as hepatitis and HIV [8].
Treatment of drug dependence has been demonstrated to
improve immune system function, significantly providing
protection from infections in general and HIV in particular [9].
Our studies concerning medical supervision and take-home
methadone indicate the need for opioid substitution to
follow specific rules to be effective with regard to behavioral
aspects [10]. Finally, adherence to antiretroviral treatment
(ART) has been reported to be significantly enhanced by stable
treatment program attendance [11,12].
Treatment of drug dependence also improves psychosocial
functioning. Two years of buprenorphine maintenance was
associated with reduced heroin use and increased housing
and employment [13]. Drug-dependence treatment also
reduced criminal activities [14] and preserved immune func-
tion [15]. Nevertheless, for those who have comorbid mental
health problems, medication for their psychiatric problem is
necessary, in addition to treatment for their substance abuse
problems. For example, the simultaneous treatment of
depression, alcoholism, and drug use can improve HIV treat-
ment adherence [11]. Additional tools, such as self-help group
participation contributes to abstinence and psychological
well-being [16]. Concomitant mental illness affecting a large
portion of drug users has been found to increase the risk of
HIV infection and reduce the rate of individuals engaged in
risk-reduction behaviors, such as using a needle exchange
program, to rates as low as 2%. In fact, scientific evidence
suggests that the effects of needle exchange programs can be
significantly enhanced through the referral of participants to
programs that treat substance use and/or other psychiatric
disorders. Our studies of addicted concomitant psychiatric
disorders (schizophrenia) showed a significant increase in the
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bidity was appropriately considered and specifically treated.
Opioid substitution treatment, needle and syringe pro-
grams, and ART applied in combination has been demon-
strated to be effective in lowering HIV transmission and
prevalence in injecting drug users [17]. Each intervention
alone will achieve modest reductions in HIV transmission,
which necessitates a combined and comprehensive approach.
Evidence for a strong association between cocaine/meth-
amphetamine use and increased risk of HIV has been
repeatedly reported. For this purpose, specific pharmacolog-
ical therapy should be made available for stimulant users
belonging to different subgroups in terms of clinical history
and personality traits. Promising medications have been
found effective in the treatment of cocaine addiction [18]. In
particular, amphetamine and dextroamphetamine, top-
iramate, disulfiram, and methylphenidate have been sug-
gested to help in the control of compulsory behavior for
stimulant addicts [19]. The combination of buprenorphine and
naltrexone to reduce cocaine craving has also recently been
the subject of experiments.5. What is needed to start substance abuse
treatment?
One can start simpledwith a nurse, a counselor, an open
door to an office that meets the basic needs of patients (food,
clothes, hygienic measures), essential medications, needles
and condoms, and educationalejob skills training. Health-
care volunteers can be a great resource. In addition to
medicine, psychosocial treatment (particularly those less
expensive and easy to organize in low-income countries) can
reduce risk behaviors and contribute to coping with stress
via a significant improvement in their immune system
function. A minimal package of psychosocial measures, such
as brief intervention, counseling, motivational interviewing,
behavioral therapy, self-help groups, and family support,
could positively contribute to the response to the HIV
epidemic.6. Conclusions
In the current economy, one should not wait for resources to
respond to the needs. Start with the minimal unit for drug-
dependence treatment, for example, with a nurse, a coun-
selor, several volunteers to provide food, essential medica-
tions, needles, and condoms, and educational or job skills
training. These interventions should include not only phar-
macological treatment and withdrawal medication, but also
basic healthcare, social assistance, and housing, as well as
social or job opportunities and skills training. These services
should be provided in the same place and managed by the
same team, with a one-stop-shop approach. It is critical to
have the passion to attract large numbers of patients and
create accessible and appealing services. In places that can
afford it, it would be ideal to have a one-stop-shop approach
that includes detoxification and maintenance medications
(methadone, buprenorphine), self-help groups, and all therelevant services, such as mental healthcare, healthcare,
dental care, therapies, vocational skill trainings and employ-
ment reintegration, social assistance, outreach and home
visiting, and overdose prevention. Finally, to move from a
moralistic approach to a science-based and compassionate
approach, we need the enthusiasm of a new generation of
professionals in addiction medicine.Disclaimer statement
This article does not necessarily reflect United Nations policy,
but only the personal view of the authors.r e f e r e n c e s
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